Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ESPRANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
ESPR(NASDAQ:ESPR) – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –
Esperion to Participate in Upcoming September Investor Conferences
ESPRANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations website.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPRANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
Esperion Reaches Settlement With Hetero USA To Delay Generic NEXLETOL Launch Until 2040, While Patent Litigation Against Additional Generic Challengers Remains Ongoing
ESPREsperion Settles Patent Litigation with Micro Labs, Preventing Generic NEXLETOL Launch Before 2040
ESPRHLS Therapeutics Agrees With Esperion Therapeutics To In-License And Commercialize NEXLETOL And NEXLIZET In Canada
ESPRNeedham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $4
ESPREsperion Therapeutics Q1 EPS $(0.21) Misses $(0.15) Estimate, Sales $65.00M Beat $54.34M Estimate
ESPRHC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
ESPRNeedham Reiterates Buy on Esperion Therapeutics, Maintains $5 Price Target
ESPREsperion Announces The Company Plans To Highlight New Research Supporting Its Lead Development Candidates For The Treatment Of Primary Sclerosing Cholangitis April 24, 2025 Today At 9:00 AM ET In New York City. Also Expands Portfolio With Introduction Of
ESPRGoldman Sachs Maintains Neutral on Esperion Therapeutics, Lowers Price Target to $3
ESPRNeedham Reiterates Buy on Esperion Therapeutics, Maintains $5 Price Target
ESPRHC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
ESPREsperion Announces Alignment With FDA On Path To Initiate Phase 3 Clinical Trials Of Bempedoic Acid Alone And In Combination With Ezetimibe
ESPRCitizens Capital Markets Reiterates Market Outperform on Esperion Therapeutics, Maintains $4 Price Target
ESPRHC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
ESPREsperion Expects Full Year 2025 Operating Expenses Of $215M-$235M, Including Approximately $15M In Non-cash Expenses Related To Stock Compensation
ESPREsperion Therapeutics Q4 2024 GAAP EPS $(0.11) Beats $(0.16) Estimate, Sales $69.11M Beat $61.58M Estimate
ESPREsperion And CSL Seqirus Partners To Commercialize NEXLETOL And NEXLIZET In Australia
ESPRHC Wainwright & Co. Reiterates Buy on Esperion Therapeuticsto Buy
ESPRHC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
ESPREsperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who Took B
ESPRHC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
ESPREuropean Commission Approve NILEMDO And Its Combination With Ezetimibe, NUSTEND For Hypercholesterolemia And Reduce Cardiovascular Risk
ESPRHC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
ESPREsperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
ESPREsperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse events, a New Drug Application is planned for late 2024.
Esperion, Otsuka Report Primary Endpoint Was Achieved In Phase 3 Trial In Japan For Bempedoic Acid As Potential Treatment For Patients With Hypercholesterolemia
ESPREsperion Therapeutics: Q1 Earnings Insights
ESPREsperion Therapeutics (NASDAQ:ESPR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Esperion Sees FY22 Operating Expenses $220M-$240M
ESPREsperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
ESPR